Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT06668324
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
The study aimed to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation.
Official title: Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
134
Start Date
2024-11-15
Completion Date
2025-09-05
Last Updated
2026-10-28
Healthy Volunteers
No
Conditions
Locations (1)
Novartis Investigative Site
East Hanover, New Jersey, United States